Lupus drug prices in focus

22 January 2021

An assessment is underway to decide the comparative clinical effectiveness and value for the US market of Aurinia Pharmaceuticals’ (TSE: AUP) voclosporin and GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) for the treatment of lupus nephritis (LN).

The USA's Institute for Clinical and Economic Review (ICER) has released a draft evidence report on the drugs, which are added to standard induction therapy for LN which is high-dose corticosteroids combined with either mycophenolate mofetil or cyclophosphamide.

Belimumab was approved by the US Food and Drug Administration (FDA) last month and its decision on voclosporin is expected in January 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK